Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma

Soltek, S.; Karakhanova, S.; Golovastova, M.; D'Haese, J.; Serba, S.; Nachtigall, I.; Philippov, P.; Werner, J.; Bazhin, A.

Авторы: Soltek S., Karakhanova S., Golovastova M., D'Haese JG, Serba S., Nachtigall I., Philippov PP, Werner J., Bazhin AV
Журнал: Naunyn Schmiedebergs Arch Pharmacol
Том: 388
Номер: 11
Год издания: 2015
Первая страница: 1121
Последняя страница: 1128
DOI: 10.1007/s00210-015-1147-9
Аннотация: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in the world. Therefore, new therapeutic options are urgently needed to improve the survival of PDAC patients. Protein kinase G (PKG) conducts the interlude of cGMP signaling which is important for healthy as well as for cancer cells. DT3 is a specific inhibitor of PKG, and it has been shown to possess an anti-tumor cytotoxic activity in vitro. The main aim of this work was to investigate anti-tumor effects of DT3 upon PDAC in vivo.Expression of PKG was assessed with real-time PCR analysis in the normal and tumor pancreatic cells. In vitro cell viability, proliferation, apoptosis, necrosis, migration, and invasion of the murine PDAC cell line Panc02 were assessed after DT3 treatment. In vivo anti-tumor effects of DT3 were investigated in the murine Panc02 orthotopic model of PDAC. Western blot analysis was used to determine the phosphorylation state of the proteins of interest.Functional PKGI is preferentially expressed in PDAC cells. DT3 was capable to reduce viability, proliferation, and migration of murine PDAC cells in vitro. At the same time, DT3 treatment did not change the viability of normal epithelial cells of murine liver. In vivo, DT3 treatment reduced the tumor volume and metastases in PDAC-bearing mice, but it was ineffective to prolong the survival of the tumor-bearing animals. In addition, DT3 treatment decreased phosphorylation of GSK-3, P38, and CREB in murine PDAC.Inhibition of PKG could be a potential therapeutic strategy for PDAC treatment which should be carefully validated in future pre-clinical studies.
Добавил в систему: Головастова Марина Олеговна

	ИСТИНА	Войти в систему Регистрация
	ФНКЦ РР
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ФНКЦ РР

Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinomaстатья

Прикрепленные файлы